88KDA tumorigenic growth factor and antagonists
AssigneeA&G Pharmaceutical, Inc.
InventorGinette Serrero
Life of this patent
Estimating the term…
Abstract
This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies.
Claims35
A method for diagnosing tumorigenicity comprising:
- measuring the expression or level of the full-length protein encoded by SEQ ID NO:
- 16 in a tissue specimen or biological fluid;
- measuring the expression or level of said protein in corresponding normal or peripheral tissue;
- and diagnosing tumorigenicity by determining whether the measured expression or level of said protein in said tissue specimen or biological fluid is higher than in corresponding normal or peripheral tissue by an amount sufficient to indicate tumorigenicity.
A method for diagnosing tumorigenicity in human breast tissue or biological fluid comprising measuring the expression or level of the full-length protein encode by SEQ ID NO:
- 16 in human tumorigenic breast tissue or biological fluid with an anti-GP88 antibody;
- measuring the expression or level of said protein in corresponding normal breast tissue or biological fluid;
- and diagnosing tumorigenicity by determining whether the measured expression or level of said protein in said tumorigenic breast tissue or biological fluid is higher than the expression or level in corresponding normal human breast tissue or biological fluid by an amount sufficient to indicate tumorigenicity.
A method for diagnosing tumorigenicity in human ovarian tissue or biological fluid comprising measuring the expression or level of the full-length protein encoded by SEQ ID NO:
- 16 in human tumorigenic ovarian tissue or biological fluid with an anti-GP88 antibody;
- measuring the expression or level of said protein in corresponding normal ovarian tissue or biological fluid;
- and diagnosing tumorigenicity by determining whether the measured expression or level of said protein in said tumorigenic ovarian tissue or biological fluid is higher than the expression or level in corresponding normal human ovarian tissue or biolgical fluid by an amount sufficient to indicate tumorigenicity.
Dependencies are inferred from the claim text.